Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHINOOK THERAPEUTICS, INC. (KDNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "CHINOOK THERAPEUTICS, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Collaboration and license revenue $ 1,828 $ 2,697 Operating expenses: Research and development 50,883 26,252 General and administrative 11,404 7,868 Change in fair value of contingent consideration and contingent value rights liabilities 526 Amortization of intangible assets 433 429 Total operating expenses 63,246 33,511 Loss from operations Investment and other income , net 3,102 Loss before income taxes and equity method investment loss Equity method investment loss Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 70..."
02/27/2023 8-K Quarterly results
Docs: "Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates SEATTLE February 27, 2023"
11/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results"
11/08/2021 8-K Quarterly results
Docs: "Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results"
08/12/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
08/03/2020 8-K Quarterly results
05/04/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Revenue – Revenue was $4.8 million for the third quarter of 2019 and $13.6 million for the nine months ended September 30, 2019, compared to $3.1 million and $12.3 million, respectively, for the same periods in 2018. The increase in revenue for the quarter and the year to date was primarily due to ratable recognition of the upfront payment received from Eli Lilly in the first quarter of 2019. • Expenses – o Research and development expenses were $15.5 million for the third quarter of 2019 and $51.9 million for the nine months ended September 30, 2019, compared to $18.7 million and $58.2 million, respectively, for the same periods in 2018. The quarter and year to date costs decreased primarily due our strategic reset in January 2019, which resulted in reduced headcount and stock-base..."
08/01/2019 8-K Quarterly results
Docs: "Cash Position – Cash, cash equivalents and marketable securities totaled $251.6 million at June 30, 2019, compared to $277.9 million at December 31, 2018. Cash spend year to date was offset by the receipt of a $12 million upfront payment received in the first quarter of 2019 from the 2018 license agreement with Eli Lilly. • Revenue – Revenue was $4.9 million for the second quarter of 2019 and $8.8 million for the six months ended June 30, 2019, compared to $2.6 million and $9.3 million, respectively, for the same periods in 2018. The increase in revenue for the quarter was primarily due to ratable recognition of the upfront payment received from Eli Lilly in the first quarter of 2019. The decrease in revenue year to date was primarily due to fluctuations in revenue recognized under ..."
05/07/2019 8-K Quarterly results
Docs: "Cash Position – Cash, cash equivalents and marketable securities totaled $266.9 million at March 31, 2019, compared to $277.9 million at December 31, 2018. Cash spend for the first quarter of 2019 included $2.2 million in one-time charges resulting from the company’s strategic reset and was offset by receipt of a $12 million upfront payment from the 2018 license agreement with Eli Lilly. • Revenue – Revenue was $3.9 million for the first quarter of 2019 compared to $6.6 million for the same period in 2018. The decrease in revenue for the period was primarily due to a $3.0 million milestone payment received from Merck in 2018 for initiation of the Phase 1 trial for the anti-CD27 antibody. The decrease was partially offset by $1.4 million in revenue recognized under the Lilly agreemen..."
02/27/2019 8-K Quarterly results
10/30/2018 8-K Quarterly results
Docs: "Aduro Biotech Reports Third Quarter 2018 Financial Results"
05/02/2018 8-K Quarterly results
Docs: "Aduro Biotech Reports First Quarter 2018 Financial Results"
10/31/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
Docs: "Aduro Biotech Reports Second Quarter 2017 Financial Results"
05/02/2017 8-K Form 8-K - Current report
11/02/2016 8-K Form 8-K - Current report
08/03/2016 8-K Form 8-K - Current report
05/02/2016 8-K Form 8-K - Current report
11/23/2015 8-K Quarterly results
Docs: "Press Release, titled “Aduro Biotech Announces Third Quarter 2015 Financial Results”"
08/10/2015 8-K Quarterly results
Docs: "Press Release, titled “Aduro Biotech Announces Second Quarter 2015 Financial Results”"
05/28/2015 8-K Quarterly results
Docs: "Aduro Biotech Announces First Quarter 2015 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy